Are Biotech M&A Premiums Already Built-In? Valuations Do Matter.
(Published this am in Seeking Alpha) Onyx Pharmaceuticals (ONXX) $10.4B Buy-Out Fuels Speculative Deal Lists We have written extensively on the life science bull market and its underpinnings: cheap money, scientific breakthroughs, sales growth and of course, M&A. The recent acquisition of...
Stocks Snap-Back After Sell-Off: NASDAQ Up 0.55%, ASTX Soars
But Uncertainty Clouds Intermediate Term Economic Outlook: Oil prices, Emerging Markets, Russia and the FED Concerns about another Middle East war and a spike in oil prices waned a bit today but many "undertoads" remain such as weak economic data, taper talk, Q4 earnings and a slowdown in...
Rayno Life Science Stocks: Deals Propel AMGN RGDX
Life science stocks resumed their upward trajectory today with major ETFs (FBT,IBB,XBI) up over 2% and a green screen for the sector. Mid-cap biopharma stocks are strong once again. The IBB hit an August low of $187 on August 19 after a high in early August near $201. Rayno Life Science stocks...
NASDAQ Trades Halted on All Stocks 2 Hour Lockdown on NASDAQ Update
Update 8/26 Best idea on securities exchanges: Randall W.Forsyth in his Barron's Up and Down Wall Street column recommends that the NASDAQ and NYSE are put under the watchful eye of the NSA. And while we are on "big data" there is news that Amazon (AMZN) has had problems with "Cloud" services...
Biotechs Rally After FED Minutes-Sharp Comeback Update—- after close
Very Strange Whipsaw Day Who is in charge of this market, humans or computers? Earlier: My biopharma screen has gone green. Maybe "taper light" scenario means buy biotech as macro and interest rates are not affected. More later but NASDAQ reversal to up 0.44%, XBI up 2.5%, FBT up 3.4%,...